12月23日晚，浙商银行发布公告称，根据中共浙江省委决定，吕临华同志任浙商银行股份有限公司党委 委员、党委副书记，提名吕临华同志任浙商银行股份有限公司董事、行长，提议陈海强同志不再担任浙 商银行股份有限公司行长职务。 公开资料显示，吕临华出生于1978年，现年47岁，拥有丰富的金融监管及银行业从业经验。其早年曾任 职于原中国保险报，还担任过原浙江保监局办公室主任、新闻发言人，以及原浙江银保监局政策法规处 负责人等职务。 2022年7月，经原浙江银保监局核准，吕临华出任浙江农商联合银行副行长，参与这一全国深化农信社 改革"第一单"的运营管理，期间还曾就科技金融发展撰写专业文章，提出"四专一生态"科技金融服务体 系建设思路。 值得注意的是，在吕临华到任后，浙商银行领导班子成员也将全部补齐。其中，陈海强将担任党委书 记、董事长，吕临华将担任党委副书记、行长，骆峰担任副行长兼董事会秘书，景峰、林静然担任副行 长，周伟新、潘华枫、王超明、侯波担任行长助理，潘华枫兼任首席风险官。 事实上，近年来，浙商银行资产规模稳步攀升，持续保持稳健扩张态势。2022年-2024年，该行资产总 额分别为26219.30亿元、31438. ...

资产规模超过3万亿元的浙商银行迎来新任行长！ 12月23日晚间，该行公告称，根据中共浙江省委决定，吕临华担任浙商银行党委委员、党委副书记，并提名董 事、行长人选，陈海强不再担任行长职务。公司董事会将尽快完成相关法定程序。 此前，51岁的陈海强已于11月中旬升任浙商银行党委书记，并获选为该行董事长。而据券商中国记者了解，吕 临华为"75后"，现年47岁。二人调整后，该行也将形成全"70后"新高管阵容。 该行相关负责人表示，此次领导班子调整，是根据省委省政府部署要求，进一步强化党对金融工作领导，加强 该行班子建设所作出的安排，有助于该行全面深化体制机制改革，推动长期行稳致远，服务好"五篇大文章"， 助力浙江省经济金融发展。 "75后"新行长 吕临华早年在原浙江保监局、原浙江银保监局任职，其间担任原浙江保监局办公室主任，并作为新闻发言人对 外发声，也曾任原浙江银保监局政策法规处负责人等职。 2022年7月，经原浙江银保监局核准，吕临华正式出任浙江农商联合银行副行长。后者作为全国深化农信社改 革的"第一单"，于2022年4月正式挂牌成立。 今年5月，吕临华在《中国金融》杂志发表《科技金融浪潮下农商银行的探索》一文指出 ...

Group 1 - The new president of Zhejiang Commercial Bank, Lü Linhua, has been nominated following the appointment of Chen Haiqiang as chairman [2] - Lü Linhua previously served as the deputy president of Zhejiang Rural Commercial Bank and has extensive experience in financial regulatory roles [2][3] - Zhejiang Rural Commercial Bank has a total asset management of 7.02 trillion yuan, with deposits of 4.93 trillion yuan and loans of 3.92 trillion yuan as of June 2025 [2] Group 2 - Lü Linhua has emphasized the importance of rural financial institutions in narrowing the urban-rural gap and promoting common prosperity in Zhejiang [3] - The bank is focusing on a multi-tiered funding supply system and inclusive financial products to support the development of new entities and industry chains [3] - The management structure of Zhejiang Commercial Bank has been further refined with key appointments, including Lü Linhua as vice secretary and proposed president [4]

智通财经APP讯，浙商银行(02016)发布公告，根据中共浙江省委决定，吕临华同志任浙商银行股份有限 公司党委委员、党委副书记，提名吕临华同志任浙商银行股份有限公司董事、行长，提议陈海强同志不 再担任浙商银行股份有限公司行长职务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 根據中共浙江省委決定，呂臨華同志任浙商銀行股份有限公司（「本公司」）黨委委 員、黨委副書記，提名呂臨華同志任浙商銀行股份有限公司董事、行長，提議陳 海強同志不再擔任浙商銀行股份有限公司行長職務。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2016） 自願性公告 關於提名董事、行長的提示性公告 本公司董事會將盡快按照法定程序完成相關工作。 承董事會命 浙商銀行股份有限公司 陳海強 執行董事、行長 CHINA ZHESHANG BANK CO., LTD. 中國，杭州 2025年12月23日 浙商銀行股份有限公司 截至本公告日期，本行的執行董事為陳海強先生及馬紅女士；非執行董事為侯興 釧先生、任志祥先生、胡天高先生及應宇翔先生；獨立非執行董事為汪煒先生、 許永斌先生、傅廷美先生、施浩先生及樓偉中先生。 ...

Core Viewpoint - The leadership transition at Zhejiang Zheshang Bank has been finalized with the appointment of Lü Linhua as the new president, following the promotion of Chen Haiqiang to chairman [1][6]. Group 1: Leadership Changes - Lü Linhua has been appointed as a member of the Party Committee, Deputy Secretary of the Party Committee, and nominated as the president of Zhejiang Zheshang Bank [1][6]. - Chen Haiqiang will no longer serve as president and will take on the role of Party Secretary and Chairman [1][6]. - The board of directors will complete the necessary legal procedures promptly [1][6]. Group 2: Background of Lü Linhua - Lü Linhua previously served as a member of the Party Committee and Vice President at Zhejiang Rural Commercial Bank since July 2022 [3][8]. - He has extensive experience in financial regulatory departments, having worked at the Zhejiang Insurance Regulatory Commission and the Zhejiang Banking Regulatory Commission [3][8]. - Under his leadership, Zhejiang Rural Commercial Bank has established a significant presence with over 4,000 outlets and more than 50,000 employees [3][9]. Group 3: Strategic Directions - The new leadership aims to implement a comprehensive financial service system, focusing on consumer and livelihood sectors, and optimizing the industrial financial service system [5][10]. - There is a commitment to deepen the bank's operations in Zhejiang and enhance its role in supporting the province's economic and financial development [5][10]. - The leadership will also focus on creating differentiated cross-border financial services and aligning with international financial centers like Shanghai and Hong Kong [5][10].

Core Insights - The article highlights the successful application of gene therapy for thalassemia by Kanglin Biotechnology, marking a significant breakthrough in the treatment of this genetic disorder in China [1][2] - It emphasizes the evolution of a supportive financial ecosystem for the biopharmaceutical industry in China, which has been crucial for the development and commercialization of innovative therapies [1][5] Group 1: Company Overview - Kanglin Biotechnology has developed gene-modified hematopoietic stem cells that have successfully restored normal hemoglobin levels in patients, eliminating their dependence on blood transfusions [1][2] - The company faced initial skepticism from the capital market due to the high costs and risks associated with biopharmaceutical research, particularly in the early stages of development [2][3] Group 2: Financial Support and Innovation - In 2019, Kanglin Biotechnology received a 5 million yuan credit loan from Zheshang Bank, which was a significant departure from traditional banking practices that typically require physical assets for collateral [3][4] - The financial support allowed Kanglin to continue its research and development, leading to the approval of clinical trials for its thalassemia gene therapy in 2024 [3][4] Group 3: Talent-Centric Financial Models - The "Talent Bank" initiative by Zheshang Bank focuses on providing financial services tailored to high-level talent, which has transformed the traditional credit assessment model from historical performance to evaluating patents and future potential [5][6] - This new financial model has resulted in a significant increase in funding for innovative companies, with over 80.9 billion yuan disbursed through "Talent Loans" in Zhejiang province alone [7][8] Group 4: Collaborative Financial Solutions - The introduction of the "Zheke United Loan" model allows multiple banks to collaborate on funding, reducing individual risk and providing more substantial support to technology enterprises [9][10] - This collaborative approach has led to the disbursement of 10.87 billion yuan in loans to technology companies, with over 30% allocated to biopharmaceutical firms [9][10] Group 5: Broader Implications for the Industry - The financial support has enabled Kanglin Biotechnology to offer its gene therapy at a fraction of the cost of similar international products, demonstrating the impact of financial backing on accessibility and affordability of innovative treatments [11][12] - The success of Kanglin's model is being mirrored in other regions, with cities in the Yangtze River Delta exploring similar financial solutions to support the biopharmaceutical sector [12]

格隆汇12月23日丨浙商银行(601916.SH)公布，根据中共浙江省委决定，吕临华同志任浙商银行股份有 限公司党委委员、党委副书记，提名吕临华同志任浙商银行股份有限公司董事、行长，提议陈海强同志 不再担任浙商银行股份有限公司行长职务。 ...

在原行长陈海强升任董事长后，浙商银行行长人选也已落定。 12月23日晚间，浙商银行（601916.SH）公告，根据中共浙江省委决定，吕临华担任浙商银行党委委员、党委副 书记，并提名董事、行长人选，陈海强不再担任行长职务。公司董事会将尽快完成相关法定程序。 在吕临华到任后，浙商银行领导班子成员将全部到位。陈海强将担任党委书记、董事长，吕临华将担任党委副书 记、行长，骆峰担任副行长、董事会秘书，景峰、林静然担任副行长，周伟新、潘华枫、王超明、侯波担任行长 助理，潘华枫兼任首席风险官。 公开信息显示，2022年7月起，吕临华在浙江农商联合银行担任党委委员、副行长。在此之前，吕临华有多年金 融监管部门工作经历，曾在浙江保监局、浙江银监局任职，担任浙江保监局办公室主任，并作为新闻发言人对外 发声。 作为全国深化农信社改革的"第一单"，2022年4月，浙江农商联合银行正式挂牌成立。目前该行下辖82家县 （市、区）农商银行、农信联社，拥有网点4000余个，金融服务点1万余家，员工5万余人。截至2025年6月末， 浙江农商银行系统全系统（含村镇银行、温州银行）管理资产总额为7.02万亿元，比去年末增加3.39%；较2024 ...

本公司董事会将尽快按照法定程序完成相关工作。 特此公告。 证券代码：601916 证券简称：浙商银行 公告编号：2025-057 浙商银行股份有限公司 关于提名董事、行长的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中共浙江省委决定，吕临华同志任浙商银行股份有限公司党委委员、 党委副书记，提名吕临华同志任浙商银行股份有限公司董事、行长，提议陈海 强同志不再担任浙商银行股份有限公司行长职务。 浙商银行股份有限公司董事会 2025 年 12 月 23 日 ...